The U.S. Food and Drug Administration accepted Cogent Biosciences’ New Drug Application for the bezuclastinib and sunitinib combination on January 20 2026, clearing a key regulatory hurdle for the company’s second‑line therapy for gastrointestinal stromal tumor (GIST) patients who have progressed on imatinib.
The acceptance follows the Phase 3 PEAK trial, which demonstrated a median progression‑free survival of 16.5 months for the combination versus 9.2 months for sunitinib alone, and an overall response rate of 46 % versus 26 %. These results suggest the combination could become the first new standard of care in this patient population in more than two decades, addressing a significant unmet need and potentially reducing the toxicity associated with current second‑line options.
Cogent’s President and CEO Andrew Robbins said the milestone “reflects the FDA’s recognition of the significant unmet need facing patients with imatinib‑resistant GIST” and that the PEAK data “have the potential to be the first new approval in this patient population in over 20 years.” Robbins added that the combination’s efficacy “offers a transformative and practice‑changing option for patients who have limited choices.”
Analysts have responded positively to the FDA acceptance, citing the robust trial data and the company’s use of the Real‑Time Oncology Review (RTOR) program, which may accelerate the review process. The breakthrough therapy designation granted in October 2025 further underscores the therapeutic promise of the combination and has bolstered confidence in the company’s pipeline.
The regulatory milestone positions Cogent to launch the product in the second half of 2026, contingent on FDA approval. With limited second‑line options and high toxicity from existing therapies, the combination could capture a sizable share of the GIST market, improving patient outcomes and strengthening the company’s commercial prospects. Cogent’s cash runway and ongoing R&D investments will support the commercialization effort, while the RTOR pathway may shorten the time to market.
The FDA acceptance under the RTOR program signals a streamlined review trajectory, potentially bringing the bezuclastinib/sunitinib combination to patients sooner than the traditional NDA process would allow. The event marks a pivotal step toward expanding treatment options for GIST and underscores Cogent’s strategy of developing targeted therapies for rare cancers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.